PATENTSCOPE will be unavailable a few hours for maintenance reason on Tuesday 19.11.2019 at 4:00 PM CET
Search International and National Patent Collections
Some content of this application is unavailable at the moment.
If this situation persists, please contact us atFeedback&Contact
1. (WO2017136421) COMBINING ELECTRONIC MONITORING WITH INHALED PHARMACOLOGICAL THERAPY TO MANAGE CARDIAC ARRHYTHMIAS INCLUDING ATRIAL FIBRILLATION
Note: Text based on automatic Optical Character Recognition processes. Please use the PDF version for legal matters

WHAT IS CLAIMED IS:

1. A method of treating cardiac arrhythmia in a subject, comprising:

(a) identifying cardiac arrhythmia in the subject with the aid of an electronic monitoring device;

(b) aerosolizing a pharmaceutical composition in less than about 9 minutes using an inhaler, wherein the pharmaceutical composition comprises of a therapeutically effective amount of at least one antiarrhythmic or a pharmaceutically acceptable salt thereof; and

(c) administering the aerosolized pharmaceutical composition to the subject; thereby treating the cardiac arrhythmia.

2. The method of claim 1, wherein the identifying of (a) includes an establishing of a duration of the cardiac arrhythmia.

3. The method of claim 2, wherein the duration of the cardiac arrhythmia is at least about 2 hours.

4. The method of claim 2, wherein the duration of the cardiac arrhythmia is at least about 1 hour.

5. The method of claim 2, wherein the duration of the cardiac arrhythmia is at least about 0.5 hours.

6. The method of claim 1, wherein the aerosolizing of the pharmaceutical

composition occurs in less than 6 minutes.

7. The method of claim 1, wherein the aerosolizing of the pharmaceutical

composition occurs in less than 3 minutes.

8. The method of claim 1, wherein the therapeutically effective amount is an

amount sufficient to convert the arrhythmia to normal sinus rhythm.

9. The method of claim 8, wherein the therapeutically effective amount is at least about 60 mg of the at least one antiarrhythmic or a pharmaceutically acceptable salt thereof.

10. The method of claim 8, wherein the therapeutically effective amount is at least about 50 mg of the at least one antiarrhythmic or a pharmaceutically acceptable salt thereof.

11. The method of claim 8, wherein the therapeutically effective amount is at least about 40 mg of the at least one antiarrhythmic or a pharmaceutically acceptable salt thereof.

12. The method of claim 8, wherein the therapeutically effective amount is at least about 30 mg of the at least one antiarrhythmic or a pharmaceutically acceptable salt thereof.

13. The method of claim 8, wherein the therapeutically effective amount converts the arrhythmia to normal sinus rhythm from about 0 sees to about 2 hours after the administration.

14. The method of claim 13, wherein the therapeutically effective amount converts the arrhythmia to normal sinus rhythm in about 60 mins after administration.

15. The method of claim 1, wherein the treating occurs within about 120 minutes from an onset of the cardiac arrhythmia.

16. The method of claim 1, wherein the treating occurs within about 90 minutes from an onset of the cardiac arrhythmia.

17. The method of claim 1, wherein the treating occurs within about 60 minutes from an onset of the cardiac arrhythmia.

18. The method of claim 1, wherein the administering comprises inhalation.

19. The method of claim 1, wherein prior to (a), an electronic monitoring chip is inserted into the subject.

20. The method of claim 1, wherein an electronic monitoring chip is worn by the subject.

21. The method of claim 19, wherein the electronic monitoring chip is in

communication with the electronic monitoring device.

22. The method of claim 21, wherein the communication is a wireless

communication.

23. The method of claim 1, wherein prior to (a), an electronic monitoring chip is inserted into the electronic monitoring device.

24. The method of claim 1, wherein the identifying of (a) comprises a

communication of a result to the subject.

25. The method of claim 24, wherein the communication comprises an instruction to administer the pharmaceutical composition.

26. The method of claim 25, wherein the instruction to administer comprises a

dosage of the aerosolized pharmaceutical composition to administer.

27. The method of claim 25, wherein the administering is performed by the subject.

28. The method of claim 25, wherein the administering is performed by a healthcare professional.

29. The method of claim 28, wherein the healthcare professional can override a recommendation made by the electronic monitoring device.

30. The method of claim 28, wherein the electronic monitoring device waits for a confirmation from the healthcare provider prior to allowing the administering of the aerosolized pharmaceutical composition to the subject.

31. The method of claim 24, wherein the communication comprises making a

treatment recommendation.

32. The method of claim 31, wherein the treatment recommendation comprises restricting the administration of the pharmaceutical composition when the electronic monitoring device does not identify an arrhythmia.

33. The method of claim 1, wherein the identifying of (a) comprises a

communication of a result to a healthcare professional.

34. The method of claim 33, wherein the administering is performed by the subject.

35. The method of claim 33, wherein the administering is performed by a healthcare professional.

36. The method of claim 35, wherein the healthcare professional is a paramedic.

37. The method of claim 35, wherein the healthcare professional is a physician.

38. The method of claim 35, wherein the healthcare professional is a monitoring professional.

39. The method of claim 33, wherein the healthcare professional can override a recommendation made by the electronic monitoring device.

40. The method of claim 33, wherein the electronic monitoring device waits for a confirmation from the healthcare provider prior to allowing the administering of the aerosolized pharmaceutical composition to the subject.

41. The method of claim 33, wherein the communication comprises making a

treatment recommendation.

42. The method of claim 41, wherein the treatment recommendation comprises

restricting the administration of the pharmaceutical composition when the electronic monitoring device does not identify an arrhythmia.

43. The method of claim 1, wherein the at least one antiarrhythmic or salt thereof is a class I antiarrhythmic.

44. The method of claim 43, wherein the class I antiarrhythmic is a class la, lb, or Ic antiarrhythmic.

45. The method of claim 43, wherein the class I antiarrhythmic is flecainide or a salt thereof.

46. The method of claim 1, wherein the at least one antiarrhythmic or salt thereof is a class II antiarrhythmic.

47. The method of claim 1, wherein the at least one antiarrhythmic or salt thereof is a class III antiarrhythmic.

48. The method of claim 1, wherein the at least one antiarrhythmic or salt thereof is a class IV antiarrhythmic.

49. The method of claim 1, wherein the at least one antiarrhythmic or salt thereof is a class V antiarrhythmic.

50. The method of claim 1, wherein the at least one antiarrhythmic or salt thereof comprises a sodium channel blocker.

51. The method of claim 1, wherein the at least one antiarrhythmic or salt thereof comprises a potassium channel blocker.

52. The method of claim 1, wherein the at least one antiarrhythmic or salt thereof comprises a calcium channel blocker.

53. The method of claim 1, wherein the at least one antiarrhythmic or salt thereof is rapidly absorbed through a subject's lungs.

54. The method of claim 53, wherein the at least one antiarrhythmic or salt thereof is delivered to a subject's heart after being absorbed through the subject's lungs.

55. The method of claim 1, wherein the inhaler is in communication with the

electronic monitoring device.

56. The method of claim 55, wherein the communication is a wired communication.

57. The method of claim 55, wherein the communication is a wireless

communication.

58. The method of claim 55, wherein the administering of the aerosolized

pharmacological composition by the inhaler is communicated to the electronic monitoring device.

59. The method of claim 58, wherein the electronic monitoring device verifies the administering of the aerosolized pharmaceutical composition.

60. The method of claim 59, wherein the electronic monitoring device continues monitoring the progress of the arrhythmia after the administration.

61. The method of claim 60, wherein a recommendation to stop the administering is communicated by the electronic monitoring device when the arrhythmia is converted to a normal sinus rhythm.

62. The method of claim 60, wherein a recommendation to seek medical attention is communicated by the electronic monitoring device when the arrhythmia is not responding to the administration of the pharmaceutical composition as determined by a continued incidence of arrhythmia at least about 2 hours after the administering.

63. The method of claim 1, wherein the electronic monitoring device comprises a digital display.

64. The method of claim 1, wherein the electronic monitoring device comprises auditory means capable of communicating to the subject.

65. The method of claim 1, wherein the electronic monitoring device is a

smartphone.

66. The method of claim 1, wherein the inhaler comprises a digital display.

67. The method of claim 1, wherein the inhaler comprises auditory means capable of communicating to the subject.

68. A system comprising:

(a) an electronic monitoring chip; wherein the electronic monitoring chip monitors incidence of arrhythmia in a subject;

(b) an electronic monitoring device; wherein the electronic monitoring

device is in wireless communication with the electronic monitoring chip; and

(c) an inhaler; wherein the electronic monitoring device is in communication with inhaler.

69. The system of claim 68, wherein the electronic monitoring device is in

communication with the inhaler through a wired connection.

70. The system of claim 68, wherein the electronic monitoring device is in

communication with the inhaler through a wireless connection.

71. The system of claim 68, wherein the electronic monitoring device comprises a digital display.

72. The system of claim 68, wherein the electronic monitoring device comprises auditory means capable of communicating to the subject.

73. The system of claim 68, wherein the electronic monitoring device is a

smartphone.

74. The system of claim 68, wherein the electronic monitoring chip is inserted into the subject.

75. The system of claim 68, wherein the electronic monitoring chip is worn by the subject.

76. The system of claim 68, wherein the inhaler comprises a digital display.

77. The system of claim 68, wherein the inhaler comprises auditory means capable of communicating to the subject.

78. The system of claim 68, wherein the electronic monitoring device comprises storage means.

79. The system of claim 78, subject data is stored using the storage means.

80. The system of claim 78, wherein the storage means is a hard drive.

81. The system of claim 78, wherein the storage means is a cloud based storage.